58 related articles for article (PubMed ID: 38466972)
1. Protocol for a pragmatic trial of Cannabidiol (CBD) to improve chronic pain symptoms among United States Veterans.
Bergmans RS; Wegryn-Jones R; Klida C; Kurtz V; Thomas L; Williams DA; Clauw DJ; Kidwell KM; Bohnert ASB; Boehnke KF
BMC Complement Med Ther; 2024 Jun; 24(1):250. PubMed ID: 38951902
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study.
Silkiss RZ; Koppinger J; Truong T; Gibson D; Tyler C
Transl Vis Sci Technol; 2023 Aug; 12(8):17. PubMed ID: 37606606
[TBL] [Abstract][Full Text] [Related]
3. The effects of acute versus repeated cannabidiol administration on trauma-relevant emotional reactivity: A double-blind, randomized, placebo-controlled trial.
Gournay LR; Ferretti ML; Nguyen AM; Bilsky S; Shields GS; Mann E; Williams P; Woychesin S; Bonn-Miller M; Leen-Feldner EW
J Trauma Stress; 2024 Jul; ():. PubMed ID: 38959155
[TBL] [Abstract][Full Text] [Related]
4. Putting the Formulation Back in Foam: Optimizing Seborrheic Dermatitis Treatment Across Diverse Hair Types.
Chovatiya R; Polaskey MT; Lain E; Schlesinger T; Woolery-Llloyd H; Burnett P; Hanna D
J Clin Aesthet Dermatol; 2024 May; 17(5):30-33. PubMed ID: 38779376
[TBL] [Abstract][Full Text] [Related]
5. Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial.
Weber I; Zagona-Prizio C; Sivesind TE; Adelman M; Szeto MD; Liu Y; Sillau SH; Bainbridge J; Klawitter J; Sempio C; Dunnick CA; Leehey MA; Dellavalle RP
JMIR Dermatol; 2024 Mar; 7():e49965. PubMed ID: 38466972
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Liu Y; Bainbridge J; Sillau S; Rajkovic S; Adkins M; Domen CH; Thompson JA; Seawalt T; Klawitter J; Sempio C; Chin G; Forman L; Fullard M; Hawkins T; Seeberger L; Newman H; Vu D; Leehey MA
Mov Disord; 2024 May; 39(5):863-875. PubMed ID: 38487964
[TBL] [Abstract][Full Text] [Related]
8. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
9. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Domen CH; Sillau S; Liu Y; Adkins M; Rajkovic S; Bainbridge J; Sempio C; Klawitter J; Leehey MA
Mov Disord; 2023 Jul; 38(7):1341-1346. PubMed ID: 37212386
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Crippa JAS; Pacheco JC; Zuardi AW; Guimarães FS; Campos AC; Osório FL; Loureiro SR; Dos Santos RG; Souza JDS; Ushirohira JM; Ferreira RR; Mancini Costa KC; Scomparin DS; Scarante FF; Pires-Dos-Santos I; Mechoulam R; Kapczinski F; Fonseca BAL; Esposito DLA; Passos ADC; Dal Fabbro AL; Bellissimo-Rodrigues F; Arruda E; Scarpelini S; Andraus MH; Nather Junior JC; Wada DT; Koenigkam-Santos M; Santos AC; Busatto Filho G; Hallak JEC
Cannabis Cannabinoid Res; 2022 Oct; 7(5):658-669. PubMed ID: 34619044
[No Abstract] [Full Text] [Related]
11. An Overview of the Diagnosis and Management of Seborrheic Dermatitis.
Dall'Oglio F; Nasca MR; Gerbino C; Micali G
Clin Cosmet Investig Dermatol; 2022; 15():1537-1548. PubMed ID: 35967915
[TBL] [Abstract][Full Text] [Related]
12. Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's Disease.
Holden SK; Domen CH; Sillau S; Liu Y; Leehey MA
Mov Disord Clin Pract; 2022 Apr; 9(3):340-350. PubMed ID: 35392299
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
de Almeida CMO; Brito MMC; Bosaipo NB; Pimentel AV; Tumas V; Zuardi AW; Crippa JAS; Hallak JEC; Eckeli AL
Mov Disord; 2021 Jul; 36(7):1711-1715. PubMed ID: 33754375
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
